# Hospital-made CAR-T under one shared regulatory master file

Source: https://onco.cc/ideas/idea-reg-point-of-care-cart-network/  
OnCo record `idea-reg-point-of-care-cart-network` (Idea). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Instead of shipping a patient's cells to a distant factory, hospitals would make CAR-T on site under a shared licence, cutting cost and waiting time.

## Summary

Academic point-of-care CAR-T already exists: ARI-0001 (Hospital Clinic Barcelona, approved under Spain's hospital exemption at roughly a third of commercial cost), NexCAR19 in India (ImmunoACT, list price around $40,000) and several Chinese and Israeli programmes. The MHRA's 2025 framework for point-of-care and modular manufacturing allows one authorisation to cover multiple hospital sites under a central control site. The proposal is a network of 20-30 hospital GMP suites making a common CD19 (and later BCMA) product from a shared master file, with pooled release testing data and a single outcomes registry.

## Fields

- Kind: Idea
- Last checked: 2026-09-08
- Hypothesis: Network-manufactured CAR-T achieves a vein-to-vein time under 14 days and a fully loaded cost per dose below $100,000 while matching the complete response rate and cytokine release syndrome profile of commercial products in the same indication.
- Rationale: The cost of autologous CAR-T is dominated by logistics, single-site capital and margin, not materials. Closed automated devices (CliniMACS Prodigy, Cocoon) make hospital manufacture reproducible, and a shared master file spreads the regulatory burden that no single hospital could carry.
- Proposed test: Fund a ten-hospital pilot in one health system with a shared control site and master file; compare vein-to-vein time, manufacturing failure rate, cost and 12-month outcomes with contemporaneous commercial CAR-T recipients in the same system.
- Maturity: early-clinical
- Actor: clinic

## Sources

- MHRA point of care manufacturing framework (page moved; nearest live section): https://www.gov.uk/government/news/

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/), [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- technologies: [CAR-T cell therapy](https://onco.cc/technologies/car-t/)
- targets: [BCMA](https://onco.cc/targets/bcma/), [CD19](https://onco.cc/targets/cd19/)
- trials: [A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)](https://onco.cc/trials/nct06464991/), [A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma](https://onco.cc/trials/nct06413498/), [CARTITUDE-4](https://onco.cc/trials/cartitude-4/), [KarMMa-3](https://onco.cc/trials/karmma-3/), [ZUMA-7](https://onco.cc/trials/zuma-7/)
- bottlenecks: [Manufacturing cost and time for living and radioactive medicines](https://onco.cc/bottlenecks/b-manufacturing-cell-therapy/), [Prices and value](https://onco.cc/bottlenecks/b-drug-pricing/)
- key papers: [CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients](https://onco.cc/key-papers/paper-cd19-all-leukemia-j-clin-invest-2016/), [CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia](https://onco.cc/key-papers/paper-cd19-all-leukemia-blood-2015/), [Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia](https://onco.cc/key-papers/paper-cd19-all-leukemia-j-clin-oncol-2014/)
- ideas: [Public payers cover academic CAR-T at cost as a benchmark for commercial prices](https://onco.cc/ideas/idea-reg-academic-cart-at-cost-coverage/)

---
JSON: https://onco.cc/api/v1/entities/idea-reg-point-of-care-cart-network.json